Status:
ACTIVE_NOT_RECRUITING
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Obesity
Eligibility:
All Genders
22-65 years
Phase:
PHASE1
Brief Summary
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight ...
Eligibility Criteria
Inclusion
- Have a BMI within the range of:
- Parts A and D: 27.0 to 45.0 kilogram per square meter (kg/m²)
- Parts B and C: 22.0 to 26.9 kg/m²
- Parts B and C: Weigh 60 kg (80 lbs) or more at screening
- Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening
- Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.
Exclusion
- Have undergone any form of bariatric surgery
- Participants who are lactating
- Have taken medications that promote weight loss within 90 days before screening
- Have a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL), 10.2 picomoles per liter (pmol/L))
Key Trial Info
Start Date :
September 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT06606106
Start Date
September 5 2024
End Date
July 1 2026
Last Update
October 16 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Collaborative Neuroscience Research, LLC
Los Alamitos, California, United States, 90720
2
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117
3
Clinical Pharmacology of Miami
Miami, Florida, United States, 33172
4
QPS
Springfield, Missouri, United States, 65802